Oncology reports最新文献

筛选
英文 中文
[Corrigendum] Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway. [更正] 麦冬呋宁 B 通过抑制 EphA2/Akt 信号通路,抑制 A549 细胞在体外和体内的转移和血管生成。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-12 DOI: 10.3892/or.2024.8774
Meijuan Chen, Cheng Hu, Yuanyuan Guo, Rilei Jiang, Huimin Jiang, Yu Zhou, Haian Fu, Mianhua Wu, Xu Zhang
{"title":"[Corrigendum] Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells <i>in vitro</i> and <i>in vivo</i> by inhibiting the EphA2/Akt signaling pathway.","authors":"Meijuan Chen, Cheng Hu, Yuanyuan Guo, Rilei Jiang, Huimin Jiang, Yu Zhou, Haian Fu, Mianhua Wu, Xu Zhang","doi":"10.3892/or.2024.8774","DOIUrl":"10.3892/or.2024.8774","url":null,"abstract":"<p><p>Subsequently to the publication of the above article, an interested reader drew to the authors' attention that, for the scratch‑wound assay experiments shown in Fig. 3C, two images appeared to overlap [specifically, the '0 h / Control' and 0 h / OP‑B (5 μmol/l) data panels], albeit with different magnification and after a 180° rotation. The authors have examined their original data, and realize that an inadvertent error was made in assembling the images in the figure; specifically, the images of 5 and 10 μmol/l OP‑B treatment for 0 h were both misused. The corrected version of Fig. 3, showing all the correct data for Fig. 3C, is shown on the next page. Note that these errors did not affect the overall conclusions reported in the paper. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of <i>Oncology Reports</i> for allowing them the opportunity to publish this. They also apologize to the readership for any inconvenience caused. [Oncology Reports 40: 1339‑1347, 2018; DOI: 10.3892/or.2018.6531].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Retracted] Circular RNA NOX4 promotes the development of colorectal cancer via the microRNA‑485‑5p/CKS1B axis. [撤稿】环状 RNA NOX4 通过 microRNA-485-5p/CKS1B 轴促进结直肠癌的发展。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.3892/or.2024.8780
Ximin Wang, Geng Tao, Donghong Huang, Shuangyin Liang, Dongxu Zheng
{"title":"[Retracted] Circular RNA NOX4 promotes the development of colorectal cancer via the microRNA‑485‑5p/CKS1B axis.","authors":"Ximin Wang, Geng Tao, Donghong Huang, Shuangyin Liang, Dongxu Zheng","doi":"10.3892/or.2024.8780","DOIUrl":"10.3892/or.2024.8780","url":null,"abstract":"<p><p>Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that there appeared to be a matching data panel comparing between one of the Transwell invasion assay experiments (the 'SW620/si‑NC' data panel) shown in Fig. 2F and Fig 6D in the following paper, written by different authors at different research institutes, that had already been published at the time of this paper's submission: Wang D, Yang T, Liu J, Liu Y, Xing N, He J, Yang J and Ai Y: Propofol inhibits the migration and invasion of glioma cells by blocking the PI3K/AKT pathway through miR‑206/ROCK1 axis. Onco Targets Ther 13: 361‑370, 2020. In addition, a potential problem regarding the design of the experiment was noted with the selection of the primers for the amplification of the miRNA miR‑485‑5p. Owing to the fact that the contentious data in the above article had already been published prior to its submission to <i>Oncology Reports</i>, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 44: 2009‑2020, 2020; DOI: 10.3892/or.2020.7758].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells. ABT-737通过ROS-ASK1-JNK MAPK信号轴提高人卵巢癌顺铂耐药A2780/DDP细胞对顺铂的敏感性。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.3892/or.2024.8781
Xiaoning Li, Yumeng Guo, Zihan Xing, Tao Gong, Lijun Yang, Tao Yang, Bingmei Chang, Xiaoxia Wang, Baofeng Yu, Rui Guo
{"title":"ABT‑737 increases cisplatin sensitivity through the ROS‑ASK1‑JNK MAPK signaling axis in human ovarian cancer cisplatin‑resistant A2780/DDP cells.","authors":"Xiaoning Li, Yumeng Guo, Zihan Xing, Tao Gong, Lijun Yang, Tao Yang, Bingmei Chang, Xiaoxia Wang, Baofeng Yu, Rui Guo","doi":"10.3892/or.2024.8781","DOIUrl":"10.3892/or.2024.8781","url":null,"abstract":"<p><p>Ovarian cancer is a gynecological malignant tumor with the highest mortality rate, and chemotherapy resistance seriously affects patient therapeutic outcomes. It has been shown that the high expression of anti‑apoptotic proteins Bcl‑2 and Bcl‑xL is closely related to ovarian cancer chemotherapy resistance. Therefore, reducing Bcl‑2 and Bcl‑xL expression levels may be essential for reversing drug resistance in ovarian cancer. ABT‑737 is a BH3‑only protein mimetic, which can effectively inhibit the expression of the anti‑apoptotic proteins Bcl‑xL and Bcl‑2. Although it has been shown that ABT‑737 can increase the sensitivity of ovarian cancer cells to cisplatin, the specific molecular mechanism remains unclear and requires further investigation. In the present study, the results revealed that ABT‑737 can significantly increase the activation levels of JNK and ASK1 induced by cisplatin in A2780/DDP cells, which are cisplatin‑resistant ovarian cancer cells. Inhibition of the JNK and ASK1 pathway could significantly reduce cisplatin cytotoxicity increased by ABT‑737 in A2780/DDP cells, while inhibiting the ASK1 pathway could reduce JNK activation. In addition, it was further determined that ABT‑737 could increase reactive oxygen species (ROS) levels in A2780/DDP cells induced by cisplatin. Furthermore, the inhibition of ROS could significantly reduce JNK and ASK1 activation and ABT‑737‑mediated increased cisplatin cytotoxicity in A2780/DDP cells. Overall, the current data identified that activation of the ROS‑ASK1‑JNK signaling axis plays an essential role in the ability of ABT‑737 to increase cisplatin sensitivity in A2780/DDP cells. Therefore, upregulation the ROS‑ASK1‑JNK signaling axis is a potentially novel molecular mechanism by which ABT‑737 can enhance cisplatin sensitivity of ovarian cancer cells. In addition, the present research can also provide new therapeutic strategies and new therapeutic targets for patients with cisplatin‑resistant ovarian cancer with high Bcl‑2/Bcl‑xL expression patterns.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Corrigendum] T7 peptide inhibits angiogenesis via downregulation of angiopoietin‑2 and autophagy. [更正] T7 肽通过下调血管生成素-2 和自噬抑制血管生成。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-19 DOI: 10.3892/or.2024.8779
Fuhai Wang, Xiaofeng Dong, Peng Xiu, Jingtao Zhong, Honglong Wei, Zongzhen Xu, Tao Li, Feng Liu, Xueying Sun, Jie Li
{"title":"[Corrigendum] T7 peptide inhibits angiogenesis via downregulation of angiopoietin‑2 and autophagy.","authors":"Fuhai Wang, Xiaofeng Dong, Peng Xiu, Jingtao Zhong, Honglong Wei, Zongzhen Xu, Tao Li, Feng Liu, Xueying Sun, Jie Li","doi":"10.3892/or.2024.8779","DOIUrl":"10.3892/or.2024.8779","url":null,"abstract":"<p><p>Following the publication of this article, an interested reader drew to the authors' attention that two pairs of protein bands featured in the western blots in Fig. 3A and 5D on p. 679 and 681 respectively appeared to be strikingly similar. After having re‑examined their original data, the authors realized that Fig. 5D had been assembled incorrectly. The revised version of Fig. 5, now including the correct data for Fig. 5D, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 5 did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree to the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, are grateful to the Editor of <i>Oncology Reports</i> for allowing them this opportunity to publish this corrigendum. They also apologize to the readership for any inconvenience caused. [Oncology Reports  33: 675‑684, 2015; DOI: 10.3892/or.2014.3653].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural products targeting ferroptosis pathways in cancer therapy (Review). 针对癌症治疗中铁蛋白沉积途径的天然产品(综述)。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-26 DOI: 10.3892/or.2024.8782
Xin Na, Lin Li, Dongmei Liu, Jiaqi He, Ling Zhang, Yiping Zhou
{"title":"Natural products targeting ferroptosis pathways in cancer therapy (Review).","authors":"Xin Na, Lin Li, Dongmei Liu, Jiaqi He, Ling Zhang, Yiping Zhou","doi":"10.3892/or.2024.8782","DOIUrl":"10.3892/or.2024.8782","url":null,"abstract":"<p><p>Ferroptosis inducers (FIN) have a key role in cancer therapy and provide novel and innovative treatment strategies. Although many researchers have performed FIN screening of synthetic compounds, studies on the identification of FIN from natural products are limited, particularly in the field of drug development and combination therapy. In this review, this gap was addressed by comprehensively summarizing recent studies on ferroptosis. The causes of ferroptosis were categorized into driving and defensive factors, elucidating key pathways and targets. Next, through summarizing research on natural products that induce ferroptosis, the study elaborated in detail on the natural products that have FIN functions. Their discovery and development were also described and insight for clinical drug development was provided. In addition, the mechanisms of action were analyzed and potential combination therapies, resistance reversal and structural enhancements were presented. By highlighting the potential of natural products in inducing ferroptosis for cancer treatment, this review may serve as a reference for utilizing these compounds against cancer. It not only showed the significance of natural products but may also promote further investigation into their therapeutic effects, thus encouraging research in this field.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Corrigendum] P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT‑related genes Snail and E‑cadherin. [更正] P2Y2 受体通过 EMT 相关基因 Snail 和 E-cadherin 促进乳腺癌细胞的迁移和侵袭。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI: 10.3892/or.2024.8770
Ying Qiu, Yan Liu, Wei-Hua Li, Hong-Quan Zhang, Xin-Xia Tian, Wei-Gang Fang
{"title":"[Corrigendum] P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT‑related genes Snail and E‑cadherin.","authors":"Ying Qiu, Yan Liu, Wei-Hua Li, Hong-Quan Zhang, Xin-Xia Tian, Wei-Gang Fang","doi":"10.3892/or.2024.8770","DOIUrl":"10.3892/or.2024.8770","url":null,"abstract":"<p><p>Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that there appeared to be two instances of overlapping data panels comparing between the cell migration and invasion assay data shown in Figs. 4 and 6 on p. 143 and 145, respectively, such that data which were intended to represent the results from differently performed experiments had apparently been derived from the same original sources. In addition, the authors themselves realized that incorrect western blotting data for Snail protein in Fig. 10A on p. 147 had been included in the figure.  The authors were able to re‑examine their original data files, and realized that the affected data panels in these figures had inadvertently been incorporated into them incorrectly. The revised versions of Figs. 4, 6, and 10, featuring the correct data for the 'NC / Control' panels in Fig. 4B and C and the 'siRNA2 / ATP 12 h' panels in Fig. 4A and B, a replacement data panel for the 'siRNA1 / Control' experiment in Fig. 6, and the correct western blotting data for Snail protein in Fig. 10A (together with a revised histogram for the MCF7 cell line relating to Fig. 10A) are shown on the next three pages. The authors wish to emphasize that the errors made in compiling these figures did not affect the overall conclusions reported in the paper, and they are grateful to the Editor of <i>Oncology Reports</i> for allowing them the opportunity to publish this corrigendum. All the authors agree to the publication of this corrigendum, and also apologize to the readership for any inconvenience caused. [Oncology Reports 39: 138‑150, 2018; DOI: 10.3892/or.2017.6081].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial‑associated endoplasmic reticulum membrane interference in ovarian cancer (Review). 卵巢癌中的线粒体相关内质网膜干扰(综述)。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI: 10.3892/or.2024.8771
Yi-Fan Dong, Jiaheng Zhang, Jin-Hong Zhou, Yi-Li Xiao, Wan-Juan Pei, Hui-Ping Liu
{"title":"Mitochondrial‑associated endoplasmic reticulum membrane interference in ovarian cancer (Review).","authors":"Yi-Fan Dong, Jiaheng Zhang, Jin-Hong Zhou, Yi-Li Xiao, Wan-Juan Pei, Hui-Ping Liu","doi":"10.3892/or.2024.8771","DOIUrl":"10.3892/or.2024.8771","url":null,"abstract":"<p><p>The mitochondria‑associated endoplasmic reticulum (ER) membrane (MAM), serving as a vital link between the mitochondria and ER, holds a pivotal role in maintaining the physiological function of these two organelles. Its specific functions encompass the participation in the biosynthesis and functional regulation of the mitochondria, calcium ion transport, lipid metabolism, oxidative stress and autophagy among numerous other facets. Scientific exploration has revealed that MAMs hold potential as effective therapeutic targets influencing the mitochondria and ER within the context of cancer therapy. The present review focused on elucidating the related pathways of mitochondrial autophagy and ER stress and their practical application in ovarian cancer, aiming to identify commonalities existing between MAMs and these pathways, thereby extending to related applications of MAMs in ovarian cancer treatment. This endeavor aimed at exploring new potential for MAMs in clinically managing ovarian cancer.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hedgehog pathway and cancer: A new area (Review). 刺猬通路与癌症:一个新领域(综述)。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-12 DOI: 10.3892/or.2024.8775
Deyi Shen, Yuwei Xia, Yuhan Fu, Qiaochang Cao, Wenqian Chen, Ying Zhu, Kaibo Guo, Leitao Sun
{"title":"Hedgehog pathway and cancer: A new area (Review).","authors":"Deyi Shen, Yuwei Xia, Yuhan Fu, Qiaochang Cao, Wenqian Chen, Ying Zhu, Kaibo Guo, Leitao Sun","doi":"10.3892/or.2024.8775","DOIUrl":"10.3892/or.2024.8775","url":null,"abstract":"<p><p>In years of research on classical pathways, the composition, information transmission mechanism, crosstalk with other pathways, and physiological and pathological effects of hedgehog (HH) pathway have been gradually clarified. HH also plays a critical role in tumor formation and development. According to the update of interpretation of tumor phenotypes, the latest relevant studies have been sorted out, to explore the specific mechanism of HH pathway in regulating different tumor phenotypes through gene mutation and signal regulation. The drugs and natural ingredients involved in regulating HH pathway were also reviewed; five approved drugs and drugs under research exert efficacy by blocking HH pathway, and at least 22 natural components have potential to treat tumors by HH pathway. Nevertheless, there is a deficiency of existing studies. The present review confirmed the great potential of HH pathway in future cancer treatment with factual basis.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of LMO7 in cancer (Review). LMO7 在癌症中的作用(综述)。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-09-01 Epub Date: 2024-07-12 DOI: 10.3892/or.2024.8776
Qun Zeng, Tingting Jiang, Jing Wang
{"title":"Role of LMO7 in cancer (Review).","authors":"Qun Zeng, Tingting Jiang, Jing Wang","doi":"10.3892/or.2024.8776","DOIUrl":"10.3892/or.2024.8776","url":null,"abstract":"<p><p>Cancer constitutes a multifaceted ailment characterized by the dysregulation of numerous genes and pathways. Among these, LIM domain only 7 (LMO7) has emerged as a significant player in various cancer types, garnering substantial attention for its involvement in tumorigenesis and cancer progression. This review endeavors to furnish a comprehensive discourse on the functional intricacies and mechanisms of LMO7 in cancer, with a particular emphasis on its potential as both a therapeutic target and prognostic indicator. It delves into the molecular attributes of LMO7, its implications in cancer etiology and the underlying mechanisms propelling its oncogenic properties. Furthermore, it underscores the extant challenges and forthcoming prospects in targeting LMO7 for combating cancer.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications and perspectives of tumor organoids in radiobiology (Review). 肿瘤有机体在放射生物学中的应用和前景(综述)。
IF 3.8 3区 医学
Oncology reports Pub Date : 2024-08-01 Epub Date: 2024-06-21 DOI: 10.3892/or.2024.8759
Jin Yu, Kailun Wang, Yongjiang Tang, Dalin Zheng
{"title":"Applications and perspectives of tumor organoids in radiobiology (Review).","authors":"Jin Yu, Kailun Wang, Yongjiang Tang, Dalin Zheng","doi":"10.3892/or.2024.8759","DOIUrl":"10.3892/or.2024.8759","url":null,"abstract":"<p><p>Radiotherapy exhibits significant versatility and efficacy in cancer treatment, thereby playing a crucial role in the field of oncology. However, there remains an urgent need for extensive research on various aspects of radiotherapy, including target selection, damage repair and its combination with immunotherapy. Particularly, the development of <i>in vitro</i> models to replicate <i>in vivo</i> tumor lesion responses is vital. The present study provides a thorough review of the establishment and application of tumor organoids in radiotherapy, aiming to explore their potential impact on cancer treatment.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 2","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信